• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CHIEF FINANCIAL OFFICER Kuhn Rebecca covered exercise/tax liability with 3,051 shares, decreasing direct ownership by 2% to 133,307 units (SEC Form 4)

    5/21/25 7:15:06 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kuhn Rebecca

    (Last) (First) (Middle)
    C/O NEUROPACE INC.
    455 N. BERNARDO AVENUE

    (Street)
    MOUNTAIN VIEW CA 94043

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NeuroPace Inc [ NPCE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/20/2025 F 3,051 D $17.99 133,307 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Leah Akin, Attorney-in-Fact 05/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NPCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroPace Continues to Strengthen Management Team

      MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

      10/16/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Strengthens Management Team with Two Key Appointments

      Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

      9/4/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Announces CEO Transition

      NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace'

      6/28/23 4:03:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 105,338 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Kuhn Rebecca covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.27% to 132,950 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:09 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.41% to 87,281 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:06 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Financials

    Live finance-specific insights

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 6:30:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 3:36:16 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      10/3/24 4:46:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    SEC Filings

    See more
    • Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NeuroPace Inc (0001528287) (Filer)

      5/27/25 8:09:45 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

      SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)

      5/15/25 8:15:55 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Neuropace Inc.

      10-Q - NeuroPace Inc (0001528287) (Filer)

      5/13/25 5:15:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • H.C. Wainwright initiated coverage on NeuroPace with a new price target

      H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

      5/28/25 9:08:28 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on NeuroPace with a new price target

      UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

      1/21/25 8:23:18 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

      3/14/24 8:11:10 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care